Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Gynecologic 2Sarcoma 1Head & Neck 1

Conditions

Lymphoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1

Interventions

Rituximab 169Cyclophosphamide 158fludarabine 76Lenalidomide 73Vincristine 70fludarabine phosphate 63Etoposide 59Doxorubicin 56Prednisone 54venetoclax 49Cytarabine 48Dexamethasone 43Filgrastim 39Peripheral Blood Stem Cell Transplantation 38Methotrexate 38Bendamustine Hydrochloride 38ibrutinib 37obinutuzumab 36Gemcitabine 31pembrolizumab 27Melphalan 27Bortezomib 27Alemtuzumab 25Radiotherapy 23Nivolumab 21Carboplatin 21Tacrolimus 20Granulocyte Colony-Stimulating Factor 20Busulfan 20Whole-Body Irradiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × ASTX-660 × Lymphoid × Clear all
NCT02503423 2026-03-20

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Taiho Oncology, Inc.

Phase 1/2 Active not recruiting
253 enrolled
GynecologicHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Lymphoma

NCT04362007 2026-02-25

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Otsuka Pharmaceutical Co., Ltd.

Phase 1/2 Terminated
8 enrolled 11 charts
Lymphoid

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡